Integration of Proteomics, Genomics, Transcriptomics and Metabonomics to identify and characterize early Prognostic, Diagnostic and Therapeutic Biomarkers for widespread Urologic Disorder founded by Eurotransbio- Network.

Chronic urologic disorders, in particular prostate / bladder carcinoma and diabetic nephropathy, have a major impact on today’s society. Their rapid increase is certainly in part owed to the high life expectancy. These diseases greatly reduce the quality of life of the affected population, and have an enormous impact on health care costs. It is expected that in the very near future costs of adequate therapy of these diseases will by far outrun the healthcare budgets, hence if the situation will not undergo any dramatic changes, then adequate treatment will not be available for all patients.
The pathobiology involves activation of a large number of genes / proteins, which interactions are not yet fully understood. Despite dramatic advances in the understanding of these diseases a considerable portion of patients cannot be treated successfully.

UroSysteomics emphasis diabetes and related comorbidities In collaboration with renowned international clinical centers urinary signatures were identified and validated for early diagnosis of diabetes and renal damage. ► read more

Novel oncological biomarkers identified In a blinded prospective study novel prostate cancer specific biomarkers were identified and validated. The survey evinced that these markers enable high sensitive und specific detection of prostate cancer.
► read more

It is necessary to offer the best treatment at the earliest moment, thereby avoiding many of the complications that are responsible for the degradation of the quality of life and for generating the costs derived from providing care to these patients. Hence, diagnosis of these urologic disorders has to be greatly, improved.. The biochemical markers available at present to establish the diagnosis and / or the follow-up of the patients at risk do not fully satisfy the expectations of the clinical practitioners taking care of the patients.
Further knowledge is required to understand the molecular mechanisms involved in diabetic nephropathy as well as in tumour appearance and progression. It is obvious that by identifying the cellular mechanisms involved in pathogenesis and tumorigenesis, new compounds, candidates to be used as markers of diagnosis and/or prognosis of diabetic nephropathies and prostate / bladder cancer or potentially to be used as targets for restricted therapy can be identified.
The identification of these targets should be carried out at the genomic, transcriptomic, proteomic and metabolomic level. It is now becoming evident that a high percentage of genes may follow unequal modulations when it relates to the gene products, the transcript or the protein. The UroSysteomics consortium will encompass all the aspects from gene to protein modulation and activity in the biology of prostate cancer. This project aims at the application and integration of high throughput technologies to identify molecular signatures with superior predictive values, reducing the number of unnecessary biopsies and allowing the stratification of patients who are susceptible to curative treatment of prostate cancer.